CAPR Shareholder Alert: Capricor Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

A securities class action alleges Capricor Therapeutics changed the pre-specified statistical analysis plan for its Phase 3 HOPE-3 trial without FDA agreement. The complaint says the FDA characterized the resulting trial analyses as post-hoc and exploratory, creating material regulatory and clinical-development risk for the company.